Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 16/20 | 0.85 |
| ▸ | CA9 | Q16790 | 16/20 | 0.85 |
| ▸ | CA2 | P00918 | 16/20 | 0.85 |
| ▸ | CA12 | O43570 | 15/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL830136 | 0.92 | CA1 (1.00) | CA1CA9CA2CA12KDM4E | |
| SCHEMBL830181 | 0.79 | CA12 (0.74) | CA1CA9CA2CA12KDM4E | |
| SCHEMBL831132 | 0.76 | CA12 (0.70) | CA1CA9CA2CA12KDM4E | |
| SCHEMBL1047082 | 0.76 | CA12 (0.70) | CA1CA9CA2CA12KDM4E | |
| SCHEMBL22273887 | 0.76 | CA12 (0.70) | CA1CA9CA2CA12KDM4E | |
| Chalcone SCHEMBL22273862 | 0.73 | CA9 (0.64) | CA1CA9CA2CA12 | |
| SCHEMBL20435590 | 0.73 | KDM4E (0.78) | CA1CA9CA2CA12KDM4E | |
| SCHEMBL852142 | 0.73 | CA12 (0.69) | CA1CA9CA2CA12NPSR1 | |
| SCHEMBL30719342 | 0.72 | CA12 (0.64) | CA1CA9CA2CA12KDM4E | |
| SCHEMBL27792013 | 0.72 | CA12 (1.00) | CA1CA9CA2CA12NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1095136-B1 | CELLS AND ANIMALS DEFICIENT IN PROTEIN KINASE C EPSILON | UNIV CALIFORNIA (US) | 2009-03-18 | — | — | EP | claimed |
| US-20180066327-A1 | Methods to Accelerate Wound Healing in Diabetic Subjects | JOSLIN DIABETES CENTER, INC. | 2018-03-08 | — | — | US | disclosed |
| EP-3268051-A1 | METHODS TO ACCELERATE WOUND HEALING IN DIABETIC SUBJECTS | Joslin Diabetes Center, Inc. (US) | 2018-01-17 | — | — | EP | disclosed |
| WO-2016149187-A1 | METHODS TO ACCELERATE WOUND HEALING IN DIABETIC SUBJECTS | JOSLIN DIABETES CENTER, INC. (US) | 2016-09-22 | — | — | WO | disclosed |
| EP-2942060-A1 | Use of Protein Kinase C Delta (PKCD) Inhibitors to Treat Diabetes, Obesity and, Hepatic Steatosis | Joslin Diabetes Center, Inc. (US) | 2015-11-11 | — | — | EP | disclosed |
| US-8598146-B2 | Methods for identifying modulators of protein kinase C-epsilon (PKCε) and method of treatment of aberrant glucose metabolism associated therewith | GARVAN INSTITUTE OF MEDICAL RESEARCH (AU) | 2013-12-03 | — | — | US | disclosed |
| US-20130281380-A1 | METHODS OF USE OF EPSILON INHIBITOR COMPOUNDS FOR THE ATTENUATION OF PAIN | KAI PHARMACEUTICALS, INC. | 2013-10-24 | — | — | US | disclosed |
| US-8492346-B2 | Methods of use of epsilon inhibitor compounds for the attenuation of pain | KAI PHARMACEUTICALS, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20130012447-A1 | PROTEIN KINASE C-DELTA INHIBITORS THAT PROTECT AGAINST CELLULAR INJURY AND INFLAMMATION AND PROMOTE ASTROCYTE PROLIFERATION | KAI PHARMACEUTICALS, INC. | 2013-01-10 | — | — | US | disclosed |
| US-8343939-B2 | Methods of modulating angiogenesis | JOSLIN DIABETES CENTER, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-6376467-B1 | PEPTIDE .EPSILON.V1-2 IS A PARTICULARLY PREFERRED INHIBITORY PEPTIDE. | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-04-23 | — | — | US | disclosed |
| EP-1095136-A1 | CELLS AND ANIMALS DEFICIENT IN PROTEIN KINASE C EPSILON | Messing, Robert O. (US) | 2001-05-02 | — | — | EP | disclosed |
| EP-1093379-A2 | USE OF INHIBITORS OF PROTEIN KINASE C EPSILON TO TREAT PAIN | Messing, Robert O. (US) | 2001-04-25 | — | — | EP | disclosed |
| WO-2000001415-A2 | USE OF INHIBITORS OF PROTEIN KINASE C EPSILON TO TREAT PAIN | MESSING ROBERT O (US) | 2000-01-13 | — | — | WO | disclosed |
| WO-2000001805-A1 | CELLS AND ANIMALS DEFICIENT IN PROTEIN KINASE C EPSILON | MESSING ROBERT O (US) | 2000-01-13 | — | — | WO | disclosed |
| WO-1994009775-A1 | NOVEL FURO-COUMARINSULFONAMIDES AS PROTEIN KINASE C INHIBITORS | SPHINX PHARMACEUTICALS CORPORATION (US) | 1994-05-11 | — | — | WO | disclosed |
| WO-1994009775-A1 | NOVEL FURO-COUMARINSULFONAMIDES AS PROTEIN KINASE C INHIBITORS | SPHINX PHARMACEUTICALS CORPORATION (US) | 1994-05-11 | — | — | WO | disclosed |
| US-5216014-A | Used for diagnosis and treatment of inflammatory, cardiovascular and neoplastic diseses | SPHINX PHARMACEUTICALS CORPORATION (US) | 1993-06-01 | — | — | US | disclosed |
| US-5216014-A | Used for diagnosis and treatment of inflammatory, cardiovascular and neoplastic diseses | SPHINX PHARMACEUTICALS CORPORATION (US) | 1993-06-01 | — | — | US | disclosed |
| US-5216014-A | Used for diagnosis and treatment of inflammatory, cardiovascular and neoplastic diseses | SPHINX PHARMACEUTICALS CORPORATION (US) | 1993-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281380-A1 | METHODS OF USE OF EPSILON INHIBITOR COMPOUNDS FOR THE ATTENUATION OF PAIN | PRKCZ, PRKCQ, PRKCE | CA1 1751/4885CA9 3889/4885CA2 792/4885 |
| US-20130012447-A1 | PROTEIN KINASE C-DELTA INHIBITORS THAT PROTECT AGAINST CELLULAR INJURY AND INFLAMMATION AND PROMOTE ASTROCYTE PROLIFERATION | PRKCD, PRKCE, PRKCQ | CA1 380/4885CA9 2060/4885CA2 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.